Alzheimer’s Disease/Dementia News

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.

Traumatic brain injury, PTSD and the apolipoprotein E4 gene showed strong associations with Alzheimer’s disease and related dementias, researchers reported in Alzheimer’s & Dementia.

Psychological distress symptoms were significantly associated with increased risk for all-cause dementia, researchers reported in JAMA Network Open.

Greater eGFR variability predicts an increased risk of death, dementia, disability and CVD events among older and healthy adults, according to data published in Kidney Medicine.

Patients with dementia who were enrolled in a practice with an interprofessional primary care team were more likely to visit the ED than those with a physician-only team, a recent study found.

People with behavioral variant frontotemporal dementia were more likely to exhibit apathy and functional decline, even in the mildest stage of dementia, compared with patients with Alzheimer’s disease, researchers recently reported.

A blood-based biomarker test aided diagnosis and clinical management of Alzheimer’s disease by detecting brain amyloidosis in symptomatic patients, researchers reported at the Clinical Trials for Alzheimer’s Disease annual meeting.

The use of restorative hearing devices for hearing loss was associated with a 19% decrease in risk for long-term cognitive decline, as well as improvement in cognitive test scores in the short term, researchers reported in JAMA Neurology.

Consuming more than 20% of total daily calories from ultra-processed foods was associated with faster decline in cognition and executive function, researchers reported in JAMA Neurology.

The Alzheimer’s Association is among a group of professional societies and research institutions that have launched the Alzheimer’s Network for Treatment and Diagnostics to collect data on patients treated with novel FDA-approved therapies.